Glenmark Pharmaceuticals inches up on the bourses

26 May 2020 Evaluate
Glenmark Pharmaceuticals is currently trading at Rs. 352.80, up by 1.00 points or 0.28% from its previous closing of Rs. 351.80 on the BSE.

The scrip opened at Rs. 355.60 and has touched a high and low of Rs. 360.40 and Rs. 347.40 respectively. So far 222697 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 575.00 on 28-May-2019 and a 52 week low of Rs. 168.00 on 13-Mar-2020.

Last one week high and low of the scrip stood at Rs. 363.60 and Rs. 325.80 respectively. The current market cap of the company is Rs. 9967.59 crore.

The promoters holding in the company stood at 46.62%, while Institutions and Non-Institutions held 35.26% and 18.12% respectively.

Glenmark Pharmaceuticals has received approval to test the combined efficacy of two antiviral drugs Favipiravir and Umifenovir as a potential COVID-19 treatment strategy. The two antiviral drugs have different mechanism of action, and their combination may demonstrate improved treatment efficacy by effectively tackling high viral loads in patients during early stage of disease.

Favipiravir is an oral antiviral drug approved in Japan since 2014 for the treatment of novel or re-emerging influenza virus infections. Umifenovir is another oral antiviral drug licensed for the treatment and prophylaxis of influenza A and B infections in Russia and China. Hence a combined use of Favipiravir and Umifenovir acting on different mechanisms offers a comprehensive antiviral cover on preentry and post-entry life-cycle of the SARS-CoV-2 virus. Both Favipiravir and Umifenovir inhibited virus infection in vitro5, 6 and have shown efficacy in COVID-19 clinical trials.

The current company’s study will examine whether early administration of a combination of Favipiravir and Umifenovir, both acting by different mechanisms, enhances antiviral efficacy on COVID-19 patients.

Glenmark Pharmaceuticals is a global pharmaceutical company. The company is engaged in the development of new chemical entities (NCEs) and new biological entities (NBEs). Its segments are India, United States, Latin America, Europe and Rest of the World (ROW).

Glenmark Pharma Share Price

1966.05 -19.30 (-0.97%)
16-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1782.80
Dr. Reddys Lab 1279.00
Cipla 1500.00
Zydus Lifesciences 913.90
Lupin 2089.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×